Clinical Trials Logo

Clinical Trial Summary

This is an open-label, phase II,multi-center study to evaluate the efficacy, safety and tolerability of KN026 in combination with KN046 in subjects with HER2-positive solid tumors.


Clinical Trial Description

KN026 is an anti-HER2 bispecific antibody that can simultaneously bind two non-overlapping epitopes of HER2, leading to a dual HER2 signal blockade.KN046 is a PD-L1 - CTLA-4 bispecific antibody. The study composes of two stages. The first stage plans to enroll HER2-positive solid tumors. All subjects will be treated with KN026 at 30 mg/kg Q3W in combination with KN046 at 5 mg/kg Q3W at the first stage.A SMC meeting will decide whether to proceed to the nest stage. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04521179
Study type Interventional
Source Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Contact
Status Completed
Phase Phase 2
Start date December 7, 2020
Completion date May 22, 2023

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04189211 - A Clinical Trial of BAT8001 on Safety, Tolerability and Pharmacokinetics for Patients Phase 1
Recruiting NCT04280341 - JS001 in Combination With RC48-ADC in Treatment of HER2-Positive Advanced Malignant Solid Tumors Phase 1
Active, not recruiting NCT04278144 - A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04660929 - CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors Phase 1
Not yet recruiting NCT04501770 - A Study of M802 (HER2 and CD3) in HER2-Positive Advanced Solid Tumors Phase 1